MedPath

Methoxy polyethylene glycol-epoetin beta

Generic Name
Methoxy polyethylene glycol-epoetin beta
Brand Names
Mircera
Drug Type
Biotech
Chemical Formula
-
CAS Number
677324-53-7
Unique Ingredient Identifier
LR3UXN0193
Background

Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.

Indication

For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.

Associated Conditions
Anemia
Associated Therapies
-

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

First Posted Date
2008-07-18
Last Posted Date
2021-09-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
421
Registration Number
NCT00717821

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Phase 2
Completed
Conditions
Renal Anemia
Interventions
First Posted Date
2008-07-17
Last Posted Date
2017-09-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
64
Registration Number
NCT00717366
Locations
🇪🇸

Hospital Universitario La Paz: Nefrologia Pediatrica, Madrid, Spain

🇮🇹

IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto, Genova, Liguria, Italy

🇪🇸

Hospital Universitario la Fe; Servicio de Nefrologia Pediatrica, Valencia, Spain

and more 36 locations

A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia

Phase 3
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-04-18
Last Posted Date
2017-12-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
132
Registration Number
NCT00661505
Locations
🇹🇷

Adnan Menderes Uni School of Medicine; Physical Therapy & Rehabilitation, Aydin, Turkey

🇹🇷

Trakya University Medical Faculty; Internal Medicine; Nephrology, Edirne, Turkey

🇹🇷

Izmir Ataturk Research and Training Hospital; The Clinic of Nephrology, Izmir, Turkey

and more 17 locations

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Phase 3
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-04-17
Last Posted Date
2016-03-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
124
Registration Number
NCT00660023

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Phase 4
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-03-25
Last Posted Date
2017-07-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
35
Registration Number
NCT00642668
Locations
🇧🇪

ZNA Stuivenberg, Antwerpen, Belgium

🇧🇪

ZNA Middelheim, Antwerpen, Belgium

🇧🇪

CH EpiCURA Site Hornu, Hornu, Belgium

and more 29 locations

A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Phase 3
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-03-25
Last Posted Date
2021-09-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
127
Registration Number
NCT00642967

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Phase 3
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-01-31
Last Posted Date
2016-05-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
101
Registration Number
NCT00605293

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Phase 3
Withdrawn
Conditions
Anemia
Interventions
First Posted Date
2007-11-19
Last Posted Date
2016-08-24
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT00560547

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis

Phase 3
Completed
Conditions
Anemia
Interventions
First Posted Date
2007-11-16
Last Posted Date
2016-04-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
184
Registration Number
NCT00559637

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Phase 3
Completed
Conditions
Renal Anemia, Chronic
Interventions
First Posted Date
2007-11-16
Last Posted Date
2016-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
307
Registration Number
NCT00559273
© Copyright 2025. All Rights Reserved by MedPath